Completed PHASE3 INTERVENTIONAL 2-arm NCT01526564

Clinical Study on Acetyl-L-Carnitine

Phase III Study of Acetyl-L-Carnitine (ALC) Hydrochloride Enteric-coated Tablets in Treatment of Peripheral Sensory Neuropathy in Anti-cancer Chemotherapeutics Induce

Sponsor: Lee's Pharmaceutical Limited

Conditions Peripheral Sensory Neuropathy

Interventions Acetylcarnitine Placebo

Updated 5 times since 2017 Last updated: Nov 7, 2013 Started: Aug 31, 2008 Primary completion: Apr 30, 2011 Completion: Jul 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01526564, this PHASE3 trial focuses on Peripheral Sensory Neuropathy and remains completed. Sponsored by Lee's Pharmaceutical Limited, it has been updated 5 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Aug 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Lee's Pharmaceutical Limited
Shanghai Changzheng Hospital
Shanghai Jiao Tong University School of Medicine

Data source: Lee's Pharmaceutical Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.